The dichotomous role of immunoproteasome in cancer: Friend or foe?

Chen, Boya; Zhu, Haiying; Yang, Bo; Cao, Ji

Chen, Boya; Zhu, Haiying; Yang, Bo; Cao, Ji.

Afiliación

Chen B; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Zhu H; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Yang B; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Cao J; The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310058, China.

Acta Pharm Sin B ; 13(5): 1976-1989, 2023 May.

Article en En | MEDLINE | ID: mdl-37250147

Palabras clave

Antigenic peptides; Cancer; Immunoproteasome; Immunotherapy; Proteasome inhibitor; Proteolysis; Targeted therapy; Ubiquitinproteasome system

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Acta Pharm Sin B Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google